Ikarian Capital, LLC Alnylam Pharmaceuticals, Inc. Put Options Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $19.4 Million - $33.4 Million	-135,200 Reduced 98.9%	1,500 $364,000
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $5.58 Million - $7.55 Million	38,100 Added 38.64%	136,700 $20.4 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $14.9 Million - $19.4 Million	98,600 New	98,600 $18.9 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $9.38 Million - $13.2 Million	-77,900 Reduced 66.13%	39,900 $5.82 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $23.2 Million - $31.7 Million	-182,200 Reduced 60.73%	117,800 $19.2 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $38.6 Million - $53.1 Million	300,000 New	300,000 $50.9 Million
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $6.34 Million - $8.78 Million	-50,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $6.06 Million - $8.27 Million	50,000 New	50,000 $7.28 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $12.5 Million - $18.8 Million	-120,300 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $11.2 Million - $16.1 Million	120,300 New	120,300 $13.1 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.